Hypoparathyroidism Treatment Market is segmented By Product Type {Parathyroid Hormone (NATPARA), Vitamin D Analogue (Vitamin D2, Vitamin D3), Calcium Supplements}; By Route of Administration (Parental, Oral); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Market Analysis, Trends, Opportunity, and Forecast, 2023-2032

Hypoparathyroidism Treatment Market Overview

The global hypoparathyroidism treatment market was valued at USD 1.49 billion in 2023. The market is expected to expand at a CAGR of 8.6% from 2023-2032, and is expected to cross value of USD 2.86 billion by the end of 2032.

Parathyroid hormone deficiency or hypoparathyroidism is a rare treatable condition that happens when an individual has a low level of parathyroid hormone in the blood. The disease lowers the level of calcium and increases the level of phosphorus in the blood. The quick rise in exigence for biologics for parathyroid hormone and the progress of modified medicines create a major scope for the growth of the market of hypothyroidism. Amgen Inc., Ascendis Pharma A/S, and BioPharma Inc. are some of the significant parties in the market for hypoparathyroidism treatment.

Hypoparathyroidism Treatment Market Drivers

Some key drivers for the hypoparathyroidism treatment market are:

• Growing Prevalence of Parathyroid Hormone Deficiency: Parathyroidism is common in women and old people. The growing prevalence of parathyroid hormone deficiency is expected to fuel the growth of the hypoparathyroidism market. 
• Increasing Need for Oral Drugs: The demand for oral drugs in the healthcare system is expected to gear the growth of the market. Oral drugs, such as capsules and tablets, are available easily and are known to be more effective for the treatment of thyroid-related diseases.
• Enhanced Technology for the Disease: Different companies are coming up with enhanced technology for treating the disease in turn boosting the growth of the market. For instance, Shire-NPS Pharmaceuticals, Inc. recently got authorization for a product for the treatment of hypoparathyroidism named NATPARA which comes as an injection to be administered in the subcutaneous layer of skin.
• Rise in Ageing Population: Hypothyroidism is common in late adolescents between the age group of 30-40 years and ageing people. Therefore, the rise in elderly people is anticipated to boost the growth of the market.

                                       Get More Insights on this report - Request Free Sample PDF

Hypoparathyroidism Treatment Market Challenges

Some challenges facing the hypoparathyroidism treatment market are:

• Complexity of Using Drugs: Presently the only drug obtainable to treat hypoparathyroidism is NATPARA. Due to its complexity including the potential risk of osteosarcoma, and reduced sensation in joints, results in hospitalization, thereby creating a challenge for the market to grow.
• Restriction in the Acceptance of Hormonal Therapy:  Commonly nowadays oral medications are a well-thought-out method to treat hypoparathyroidism restricting the acceptance of hormonal therapy given to patients at the high cost of injections, which in turn, is obstructing the growth of the market.
• Time-Taking Clinical Processes: All the medicines or drugs used to treat hypothyroidism undergo certain clinical processes which takes time to get approval from the respective agency, thereby restraining the growth of the market.

Hypoparathyroidism Treatment Market Segmentation

Segmentation of hypoparathyroidism treatment market are:

• By Product type
  • Parathyroid hormone (NATPARA)
  • Vitamin D Analogue (Vitamin D2, Vitamin D3)
  • Calcium supplements

•  By Route of administration
  • (parental, oral)
• By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • online
• By Region
  • North America (U.S., and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Middle East and Africa

Timeline considered for all these studies will be:

2023 – Base Year

2023 – Estimated Year

2023-2032 – Forecast Period

Hypoparathyroidism Treatment Market Regional Synopsis

Thyroid-related diseases are soaring high in North America. Moreover, greater initiatives are taken by the pharmacological departments of the region for innovating new drugs. Such factors are therefore anticipated to help the hypoparathyroidism treatment market in North America register the largest share by 2032.

Further, the market in the Asia Pacific region is expected to register the second-largest market share. The government and different pharmaceutical organizations are taking necessary steps to create consciousness about the disease. Also, the pharmaceutical drug manufacturers are ensuring to make the availability of different drugs for treating the disease, which is also expected to contribute to the expanding market share.

Hypoparathyroidism Treatment Market Key Players

Some key players in the hypoparathyroidism treatment market are:

• Amgen Inc.
• Ascendis Pharma A/S
• Biopharma
• EnteraBio Ltd.
• Exten Biosciences, Inc.
• F.Hoffmann-La Roche Ltd.
• ProLynx Inc.
• Takeda Pharmaceutical Company Limited 
• Teva Pharmaceuticals Ltd.
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• GSK plc
• EnteraBio Inc.
• AbbVie Inc.
• WCCT Global Inc.